Matthias Aizenberg

Every three minutes somewhere in the world, a person with type 1 diabetes calculates a dose of insulin and still lives with the nagging reality that even perfect math will not reproduce the split-second precision of native β-cells. Clinicians point to the autoimmune destruction that erased those

A daily habit as ordinary as pouring a third or fourth cup of coffee may have aligned with a five-year edge in biological aging among people living with schizophrenia and mood disorders, hinting that moderation could matter more than any exotic supplement. The notion is surprising because coffee

Glioblastoma care has long run up against a biological wall that blunts even the best therapies, and a new approach that pries open that wall just long enough to let drugs in now looks like a genuine shift rather than a lab curiosity. Patients still face a dire prognosis despite aggressive surgery

In a world where patients often wait nearly a year for life-saving drugs to gain approval, a groundbreaking initiative by the FDA is slashing that timeline to mere weeks, promising a dramatic shift in biopharma. The Commissioner’s National Priority Voucher (CNPV) pilot program is not just speeding

I'm thrilled to sit down with Ivan Kairatov, a biopharma expert with a profound understanding of technology and innovation in the healthcare industry. With a robust background in research and development, Ivan has been at the forefront of exploring how artificial intelligence can transform

In a world where Alzheimer’s disease continues to challenge medical science with its relentless progression and devastating impact on millions of lives, the search for effective treatments remains a top priority for researchers and pharmaceutical companies alike. Recent developments have sparked

Japan stands at the forefront of a digital transformation that is reshaping the very foundation of its healthcare system, with the My Number card serving as a pivotal tool in this evolution, initially designed for social security and tax purposes. This national identification card has now become an

What happens when a beacon of hope for millions battling multiple sclerosis (MS) dims in a single clinical trial? In a field where breakthroughs are rare and desperately needed, Contineum Therapeutics, a San Diego-based biotech firm, has hit a significant roadblock with their lead drug, PIPE-307,

I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in tech and innovation within the healthcare industry. With a strong background in research and development, Ivan brings a unique perspective on the evolving landscape of telehealth and pharmaceutical

The landscape of oncology treatment is witnessing a transformative shift with Johnson & Johnson (J&J) securing a positive recommendation from the UK’s National Institute for Health and Care Excellence (NICE) for its groundbreaking therapy, TALVEY (talquetamab). This approval for use within the